NEW YORK (GenomeWeb News) – Ignyta said on Monday it has acquired biotech firm Actagene for an undisclosed amount.

The deal, according to Ignyta, will transition it from a company focused solely on molecular diagnostics for autoimmune diseases to "an integrated Rx/Dx focus on drug and biomarker discovery and development for cancer and immunology."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.